No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract Daratumumab, Lenalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Cytogenetic Subgroup Analysis from POLLUX

byKathleen Lau

December 10, 2020

in StudyGraphics

#VisualAbstract: Increased incidence of sebaceous carcinomas among solid organ transplant recipients

RelatedReports

Variation noted across pre- and post-marketing studies for FDA approved devices

AI Roundup

Artificial intelligence accelerates drug discovery and reduces animal testing

September 12, 2025

Oncology

Royalty financing deepens exposure to small cell lung cancer revenues

September 8, 2025

2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]

Cardiology

2 Minute Medicine: Pharma Roundup- Obesity RNA deal, at-home Alzheimer’s dosing, oncology royalty financing, and first Bruton’s Tyrosine Kinase Inhibitor for Immune Thrombocytopenia [September 3, 2025]

September 3, 2025

Brain lesions on MRI linked with subsequent increased stroke risk

Neurology

Moderate to severe TBI is associated with elevated malignant brain tumor risk

September 1, 2025

Oxygenated hypothermic perfusion reduces post-kidney transplant complications

Quick Take: Diffusion-weighted Imaging of Invasive Breast Cancer: Relationship to Distant Metastasis–free Survival

Pembrolizumab plus chemotherapy improves survival in patients with metastatic triple-negative breast cancer

$#VisualAbstract CONTRALTO Phase II: Venetoclax-Rituximab With or Without Bendamustine VS Bendamustine-Rituximab in Relapsed/Refractory Follicular Lymphoma$

#VisualAbstract CONTRALTO Phase II: Venetoclax-Rituximab With or Without Bendamustine VS Bendamustine-Rituximab in Relapsed/Refractory Follicular Lymphoma

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports